Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 7:28 PM ET


Company Overview of OvaScience, Inc.

Company Overview

OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries;...

215 First Street

Suite 240

Cambridge, MA 02142

United States

Founded in 2011

52 Employees



Key Executives for OvaScience, Inc.

Co-Founder, Chief Executive Officer and Director
Age: 39
President and Chief Scientific Officer
Total Annual Compensation: $644.0K
Compensation as of Fiscal Year 2014.

OvaScience, Inc. Key Developments

OvaScience, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

OvaScience, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. Net loss for the three months ended September 30, 2015 was $17.9 million, or $0.66 per basic and diluted share, as compared to net loss of $12.9 million, or $0.54 per basic and diluted share, for the three months ended September 30, 2014. The increase in net loss is primarily attributable to planned higher personnel costs, stock-based compensation, and costs associated with the launch of the AUGMENT treatment in certain international IVF clinics. For the quarter, the company reported revenue of $0.075 million. Loss from operations was of $17.772 million compared to $12.399 million a year ago. For nine months, the company reported revenue of $0.120 against $0.00 a year ago. Loss from operations was of $51.759 million compared to $29.644 million a year ago. Net loss was $52.618 million or $1.95 per basic and diluted share compared to $30.630 million or $1.38 per basic and diluted share a year ago.

OvaScience, Inc. - Special Call

To provide an update on corporate goal for AUGMENT Treatment

OvaScience, Inc. Presents at Boston Biotech Conferences 2015, Nov-11-2015

OvaScience, Inc. Presents at Boston Biotech Conferences 2015, Nov-11-2015. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States. Presentation Date & Speakers: Nov-11-2015, Theresa McNeely, Chief Communications Officer and Executive Vice President. Nov-12-2015, Arthur Tzianabos, President and Chief Scientific Officer.

Similar Private Companies By Industry

Company Name Region
Implicit Bioscience, Inc. United States
Transcription Factor Therapeutics, Inc. United States
Gencia Corporation United States
Mercator MedSystems, Inc. United States
Bioral Nutrient Delivery, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OvaScience, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at